JPMorgan Chase & Co. Purchases 12,029 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

JPMorgan Chase & Co. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 17.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 79,780 shares of the company’s stock after purchasing an additional 12,029 shares during the period. JPMorgan Chase & Co.’s holdings in IDEAYA Biosciences were worth $2,527,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in IDYA. Envestnet Asset Management Inc. increased its position in IDEAYA Biosciences by 24.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 104,553 shares of the company’s stock worth $3,671,000 after buying an additional 20,607 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of IDEAYA Biosciences in the second quarter worth $3,838,000. Hsbc Holdings PLC increased its position in IDEAYA Biosciences by 80.1% during the second quarter. Hsbc Holdings PLC now owns 15,269 shares of the company’s stock worth $528,000 after acquiring an additional 6,789 shares during the period. Magnetar Financial LLC acquired a new position in IDEAYA Biosciences during the 2nd quarter valued at $1,599,000. Finally, Logos Global Management LP boosted its holdings in IDEAYA Biosciences by 13.3% in the 2nd quarter. Logos Global Management LP now owns 1,700,000 shares of the company’s stock valued at $59,687,000 after purchasing an additional 200,000 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on IDYA. Cantor Fitzgerald restated an “overweight” rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, December 17th. Leerink Partners lowered IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Royal Bank of Canada restated an “outperform” rating and issued a $61.00 target price on shares of IDEAYA Biosciences in a research note on Wednesday, January 15th. Finally, Stephens began coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They issued an “overweight” rating and a $51.00 target price for the company. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.67.

IDEAYA Biosciences Trading Down 2.4 %

NASDAQ IDYA opened at $22.18 on Tuesday. IDEAYA Biosciences, Inc. has a 1-year low of $22.10 and a 1-year high of $47.74. The company has a 50 day moving average of $26.14 and a 200-day moving average of $32.23. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -9.52 and a beta of 0.82.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.03. During the same period in the prior year, the company posted ($0.46) earnings per share. On average, analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 earnings per share for the current year.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.